Weave Communications, Inc. WEAV R2K
Weave Communications, Inc. operates an AI-powered patient communications, engagement, and payments platform for small and medium-sized healthcare businesses. It offers AI-receptionist; Unified Phone Number; Customized Phone System, a smarter phone system to identify whether incoming calls are from new or current patients, provide information at every call, and manage heavy call times; Softphones to make and receive calls from anywhere with an internet connection; Text Messaging and SMS response assistant; Missed Call Text that allows practices to respond when a call is missed; Missed Text Auto-Reply that replies to patient text messages by automatically responding to messages received outside of a practice's normal operating hours; Team Chat, a group messaging solution; and Weave Mobile App. It also provides Weave Reviews and Respond Assistant to request, collect, monitor, and respond to reviews; Weave Email Marketing and Email Assistant to create professional emails; Text Connect to interact with their patients online directly through their websites; and Weave Payments, a payment processing solution. The company provides Weave Digital Forms to collect patient information; Online Scheduling that allows patients to request appointments from the practice's website, send automatic scheduling reminders, and personalize each reminder for the patient; Insurance Eligibility, an insurance tool; Insurance Verification; Practice Analytics that provides real-time data on patient retention, appointment scheduling, treatment acceptance rates, and revenue generation; Call Intelligence; and Weave Enterprise for multi-location healthcare practices comprising dental service organizations, vision, veterinary, and medical groups. The company was formerly known as Recall Solutions, LLC and changed its name to Weave Communications, Inc. in October 2015. Weave Communications, Inc. was founded in 2008 and is headquartered in Lehi, Utah.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 18.9% over 5 years.
- Profit CAGR of 14.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 39.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WEAV Weave Communications, Inc. R2K | 6.02 | - | $478.99M | - | -22.11% | -32.92% | 18.92% | 14.53% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.39M | 25.67M | - | 30.30M | - | 33.27M | - | - | - | - | - | - | - | - | 55.81M | 58.47M | 61.34M | 63.40M | 65.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.86M | 16.52M | 17.00M | 17.33M | 17.96M |
| Gross Profit | 12.17M | 14.87M | 16.04M | 17.43M | - | 19.52M | 21.18M | 23.21M | 26.53M | 28.04M | 29.93M | 32.99M | 36.12M | 37.73M | 39.95M | 41.95M | 44.34M | 46.07M | 47.54M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.27M | 52.14M | 53.29M | 48.23M | 53.56M |
| Operating Income | -10.15M | -8.71M | -14.13M | -13.90M | - | -13.51M | -14.59M | -11.86M | -8.52M | -9.83M | -8.02M | -8.15M | -9.26M | -6.63M | -9.32M | -10.19M | -8.94M | -2.16M | -6.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.57M | -5.26M | -3.95M | 3.00M | -772.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 397.00K | 537.00K | 366.00K | 400.00K | 369.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.75M | -9.82M | -8.59M | -1.82M | -5.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.00K | -1.11M | 82.00K | 29.00K | 102.00K |
| Net Income | -10.40M | -8.98M | -14.42M | -14.22M | - | -13.84M | -14.81M | -11.82M | -7.86M | -8.99M | -7.14M | -7.20M | -8.55M | -5.88M | -8.82M | -8.71M | -8.67M | -1.85M | -5.77M |
| Diluted EPS | -0.95 | -0.79 | -1.12 | -1.03 | -2.60 | -0.21 | -0.23 | -0.18 | -0.12 | -0.13 | -0.10 | -0.10 | -0.12 | -0.08 | -0.12 | -0.11 | -0.11 | -0.02 | -0.07 |
| R&D Expense | 5.41M | 5.84M | 7.87M | 6.18M | - | 7.20M | 7.43M | 7.90M | 7.69M | 8.59M | 8.63M | 9.64M | 9.96M | 9.87M | 11.15M | 11.99M | 13.12M | - | 10.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 45.75M | 79.90M | - | 142.12M | 170.47M | 204.31M | 239.02M |
| Cost of Revenue | - | - | - | 53.28M | 54.38M | 58.43M | 66.72M |
| Gross Profit | 27.23M | 45.45M | - | 88.84M | 116.09M | 145.88M | 172.31M |
| Operating Expenses | - | - | - | 138.54M | 150.46M | 177.29M | 202.92M |
| Operating Income | -31.92M | -39.57M | - | -49.70M | -34.37M | -31.41M | -30.61M |
| EBITDA | - | - | - | -31.55M | -13.02M | -11.17M | -10.78M |
| Interest Expense | - | - | - | 1.44M | 1.92M | 1.52M | 1.70M |
| Pretax Income | - | - | - | -49.63M | -30.77M | -28.16M | -28.98M |
| Tax Provision | - | - | - | 104.00K | 260.00K | 189.00K | -924.00K |
| Net Income | -32.06M | -40.42M | - | -49.74M | -31.03M | -28.35M | -28.05M |
| Diluted EPS | -3.30 | -3.75 | - | -0.76 | -0.46 | -0.40 | -0.37 |
| R&D Expense | 14.41M | 19.97M | 27.01M | 30.71M | 34.04M | 40.23M | 44.46M |
Compounded Sales Growth
| 5 Years: | 18.92% |
| 1 Year: | 17.40% |
Compounded Profit Growth
| 5 Years: | 14.53% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -37.62% |
| 6 Months: | -4.60% |
| 3 Months: | +19.44% |
| 1 Month: | +24.38% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 92.97M | - | 208.35M | 201.01M | 188.93M | 207.97M |
| Current Assets | - | - | - | - | 132.89M | 129.78M | 120.74M | 104.99M |
| Cash & Equivalents | - | - | 55.70M | - | 62.00M | 50.76M | 51.60M | 54.96M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 3.30M | 3.51M | 3.74M | 4.35M |
| Total Liabilities | - | - | 54.98M | - | 125.13M | 122.06M | 121.96M | 125.58M |
| Current Liabilities | - | - | 44.02M | - | 72.22M | 72.85M | 76.62M | 84.60M |
| Long Term Debt | - | - | 3.60M | 10.00M | - | - | - | - |
| Total Debt | - | - | - | - | 73.56M | 59.54M | 56.06M | 52.15M |
| Total Equity | -61.91M | -85.99M | -113.94M | - | 83.22M | 78.96M | 66.97M | 82.38M |
| Shares Outstanding | - | - | - | - | 65.74M | 70.12M | 73.23M | 78.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.07M | -15.52M | - | -12.77M | 10.22M | 14.15M | 17.54M |
| Investing Cash Flow | -2.47M | -3.86M | - | -54.03M | -7.74M | 8.88M | -6.85M |
| Financing Cash Flow | 65.00M | -5.15M | - | -7.21M | -13.72M | -22.19M | -7.33M |
| Capital Expenditure | -2.47M | -2.76M | - | -3.13M | -3.69M | -3.79M | -4.68M |
| Free Cash Flow | -24.54M | -18.28M | - | -15.89M | 6.53M | 10.36M | 12.86M |
| Net Change in Cash | - | - | - | -74.00M | -11.24M | 840.00K | 3.36M |
| Share Buybacks | 1.41M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 59.5% | 56.9% | - | 62.5% | 68.1% | 71.4% | 72.1% |
| Operating Margin % | -69.8% | -49.5% | - | -35.0% | -20.2% | -15.4% | -12.8% |
| Net Margin % | -70.1% | -50.6% | - | -35.0% | -18.2% | -13.9% | -11.7% |
| ROE % | 37.3% | 35.5% | - | -59.8% | -39.3% | -42.3% | -34.1% |
| ROCE % | - | -80.8% | - | -36.5% | -26.8% | -28.0% | -24.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Newtyn Management, Llc | 8.80% | 7.00M | $42.14M |
| 2 | Blackrock Inc. | 5.93% | 4.72M | $28.42M |
| 3 | Crosslink Capital Inc | 5.34% | 4.25M | $25.57M |
| 4 | Gumshoe Capital Management LLC | 3.86% | 3.07M | $18.48M |
| 5 | Vanguard Capital Management LLC | 3.47% | 2.76M | $16.62M |
| 6 | Vanguard Portfolio Management LLC | 3.05% | 2.43M | $14.62M |
| 7 | Disciplined Growth Investors, Inc. | 2.86% | 2.28M | $13.70M |
| 8 | State Street Corporation | 2.76% | 2.19M | $13.20M |
| 9 | Frontier Capital Management Company LLC | 2.64% | 2.10M | $12.64M |
| 10 | Divisar Capital Management LLC | 2.31% | 1.84M | $11.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WEAV